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Abstract
Human colorectal cancer (CRC) arises from activating mutations in the Wnt/β-catenin pathway that converge with
additional molecular changes to shape tumor development and patient prognosis. We report here that Na+/H+
exchanger 3 regulating factor 1 (NHERF1)/EBP50, an adaptor molecule that interacts with β-catenin, undergoes
successive alterations during the colorectal adenoma-to-carcinoma transition, ranging from loss of normal apical
membrane distribution to ectopic cytoplasmic overexpression. NHERF1 depletion in human intestinal epithelial
polarized cells induced epithelial-mesenchymal transition, β-catenin nuclear translocation with elevation of Wnt/β-
catenin transcriptional targets, and increased cell migration and invasion. Ectopic cytoplasmic NHERF1 expression
additionally intensified the transformed phenotype by increasing cell proliferation. The epithelial morphology and
reduced cell motility could only be restored by re-expression of NHERF1 specifically at the apical plasmamembrane.
We conclude that alterations in the apical membrane localization of NHERF1 contribute to CRC through the disrup-
tion of epithelial morphology. This study identifies NHERF1 as a new player in CRC progression and supports the
notion that the expression or subcellular distribution of NHERF1 may be used as diagnostic marker for CRC.
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Introduction
Human colorectal cancer (CRC) is the third most common type of can-
cer and the third cause of mortality due to cancer in the United States
[1]. It typically evolves from a benign polyp, or adenoma, to malignant
carcinoma that starts in the mucosa (carcinoma in situ) and spreads
through the other layers of the colon. In advanced stages, malignant cells
metastasize to the lymph nodes or to distant organs. The ability of CRC
cells to invade and metastasize renders the tumors unresectable and
resistant to chemotherapy and diminishes abruptly the overall survival
rate for patients withmetastatic disease to approximately 10% at 5 years.
The acquired invasiveness ofmalignant cells results from the disorgani-
zation of epithelial morphology leading to an epithelial-mesenchymal–
like transition (EMT) [2]. This process occurs naturally during the
embryonic development of some structures and is reactivated in ma-
lignant cells of epithelial origin. In neoplastic cells, EMT is reflected by
various degrees of epithelial change, from mild loss of cell polarity
to the acquisition of frank mesenchymal/fibroblastic characteristics
with increased cell motility [3]. The main event in EMT is the loss
of E-cadherin from adherens junctions, and several pathways have
been involved in triggering it [4]. The Wnt/β-catenin pathway can
promote EMT through activation of the Slug and Snail transcription
factors, which are known to repress the E-cadherin promoter [5,6].
Both Slug and Snail have been shown to be upregulated in advanced
CRC tumors [7,8]. Wnt/β-catenin signaling also activates promoters
of genes usually expressed in fibroblasts that enhance invasiveness,
such as fibronectin and matrix metalloproteinase 7 (MMP7) [4].
Abbreviations: CRC, colorectal cancer; EMT, epithelial-mesenchymal transition; ERM,
ezrin-radixin-moesin; IF, immunofluorescence; MMP, matrix metalloproteinase;
NHERF1, Na+/H+ exchanger 3 regulating factor 1; PDZ, PSD-95/Disc-large/ZO-1;
PM, plasma membrane
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TheWnt/β-catenin pathway is activated in more than 90% of CRCs
by mutations in either the Apc gene (80%-85%) or the gene encoding
β-catenin (5%-10%) [9]. These mutations interfere with the degrada-
tion of cytoplasmic β-catenin, allowing its translocation to the nucleus
and the subsequent activation of genes involved in proliferation and
EMT. However, the pathology of CRC is complex and cannot be fully
explained by this central pathway alone [10]. Modifying influences are
present within and outside the Wnt/β-catenin central pathway, and
we investigate here whether NHERF1/EBP50 (Na+/H+ exchanger 3
regulating factor 1; ezrin-radixin-moesin (ERM) binding phospho-
protein 50), an adaptor protein that interacts directly with β-catenin
[11], plays a role in CRC.
NHERF1 is a 50-kDa adaptor protein composed of two tandem
PSD-95/Disc-large/ZO-1 (PDZ) domains and a carboxyl (C)-terminal
ERM-binding region [12,13]. It associates with β-catenin through its
PDZ2 domain [11] and with ezrin through its ERM-binding re-
gion [12]. NHERF1 is localizedmainly at the apical plasmamembrane
(PM) in human epithelial tissues [14] and its inactivation in mice in-
duces ultrastructural abnormalities of the intestinal brush bordermem-
brane [15,16]. Our previous studies in mouse embryonic fibroblasts
showed that NHERF1 behaves as a tumor suppressor through its ef-
fects on β-catenin and PTEN [17,18]. We have now examined the
involvement of NHERF1 in human CRC, first by examining patient
tumor samples for changes in the expression and intracellular distribu-
tion of NHERF1 and second by modeling these changes in polarized
intestinal epithelial cells. The NHERF1 alterations observed in CRC
induced a malignant cell phenotype, implicating NHERF1 as a new
and important modifier of CRC progression.
Materials and Methods
CRC Resection Specimens
A total of 18 tissue resection specimens from patients with CRC
(6 men and 12 women, 63.3 ± 2.3 years) were obtained from the
CRC Bank at MD Anderson Cancer Center. Surgeries for all cases
had been performed in a 15-year period between 1992 and 2007,
and no patient received previous therapy. Of the 18 specimens, 11
were paraffin-embedded, with areas of adenoma, carcinoma, and adja-
cent normal mucosa on the same slide. The remaining seven cases were
matched sets of frozen specimens with the pathologist’s annotations as
normal, deep tumor (carcinoma), and tumor edge (adenoma).
Immunofluorescence (IF)
The CRC specimens were deparaffinized and hydrated as previously
described [17], followed by antigen retrieval in a steamer for 20 min-
utes. The sections were cooled for 10 minutes, rinsed with ddH2O for
5 minutes three times, and blocked from nonspecific binding for
30 minutes with 20% to 50% donkey serum in PBS. The NHERF1
antibody (Affinity BioReagents/Thermo, Rockford, IL) was applied at
1:200 in PBS overnight at 4°C, and unbound antibody was removed
by washing three times with PBS for 5 minutes. The secondary anti-
body, Alexa Fluor 488 donkey antirabbit IgG (Molecular Probes/
Invitrogen, Carlsbad, CA), was applied at 1:500 in PBS for 45minutes
followed by three PBS washes for 5 minutes. The sections were incu-
bated in ToPro-3 iodide (Molecular Probes/Invitrogen) at 1:2000 in
PBS for 20 minutes for nuclear staining and were then washed twice
with PBS for 5 minutes. The Slowfade Gold antifade reagent (Molec-
ular Probes/Invitrogen) was used for themounting of the slides. Images
were acquired with the Zeiss 510 confocal microscope (Carl Zeiss
MicroImaging, Thornwood, NY), using 40×/1.30 objective with oil
immersion. The densitometric analysis of the IF intensity was per-
formed with the ImageJ software (National Institutes of Health,
Bethesda, MD).
Cells, Plasmids, and Retroviral Infections
The Caco-2, HT29, and RKOhuman CRC cell lines were grown in
Dulbecco modified Eagle medium/Ham’s F-12 nutrients (DMEM/
F-12) supplemented with 10% FBS. The 293T cells were grown in
DMEM supplemented with 10% FBS. The retroviral construct en-
coding wild-type NHERF1 (358 residues) in the pCXb vector (blasti-
cidin selection) was described elsewhere [17]. The short hairpin RNA
(shRNA) 1 (ACCCCATCCTAGACTTCAA) and 4 (GGGAAACT-
GACGAGTTCTT) used for NHERF1 knockdown were cloned in
pSIREN-RetroQ vector (puromycin selection) [19]. The pSIREN-
RetroQ control vector carries an irrelevant shRNA for enhanced
green fluorescent protein. The myristoylation signal of v-Src,
MGSSKSKPKDPSQR, was added N-terminally to NHERF1 in the
pCXb vector, generating Myr-NHERF1. The Myr signal was also
added to the NHERF1 PDZ1-2 construct that lacks the terminal
ERM-binding region. Transfections and retroviral infections were per-
formed as previously described [20]. All functional assays were per-
formed on cell pools resulting after selection of infected cells with
the appropriate selection marker.
Cell Morphology, Migration, and Invasion Assays
For assessment of cell morphology, 5 × 105 cells in 2% FBSDMEM
were plated in duplicate in six-well dishes and cultured for 10 days at
37°C. On day 10, cells were washed with PBS twice, fixed in 10%
acetic acid for 20 minutes, washed with PBS once, and stained with
0.1% crystal violet for 20 minutes. Cell migration was assessed by
scratching a confluent cell monolayer with a 2- to 200-μl tip in
serum-free DMEM. The width of the scratch was measured at differ-
ent time points with ImageJ software. For cell invasion, 1 × 106 cells
were prepared in duplicate in 250 μl of serum-free DMEM. The cells
were placed in transwells with 8-μm pore size polycarbonate fil-
ters (Corning Incorporated, Corning, NY), precoated with 100 μl of
0.7mg/mlMatrigel (BDBiosciences, San Jose, CA). To obtain a chemo-
gradient across the transwells, the lower wells were filled with 750 μl of
10% FBS DMEM. The cells were incubated at 37°C for 48 hours,
fixed with methanol, and stained with hematoxylin and eosin
(H&E). Nonmigratory cells on the upper surface of the transwells were
removed with a cotton swab, and the number of cells remaining on
the lower surface of the transwell was counted.
Gelatin Zymography
To analyze the activity of secreted MMPs, 2.5 × 105 cells in
10% FBS DMEM were plated in 12-well dishes, incubated overnight
at 37°C, and changed in serum-free DMEM for 24 hours. This was
collected and spun at 10,000g for 5 minutes. The cell-free supernatant
was normalized to the cell number, and equivalent amounts were
loaded without boiling on a 12% polyacrylamide gel copolymerized
with 1 mg/ml gelatin and separated in nonreducing conditions. The
gel was washed twice for 30 minutes in 2.5% Triton X buffer with
50 mM Tris (pH 7.5), 5 mM CaCl2, 1 μM ZnCl2, and 0.02% NaN3.
It was then equilibrated for 30 minutes at room temperature in the
same buffer devoid of 1% Triton X, thereafter incubated in this buffer
for 48 hours at 37°C. Coomassie blue was used to stain the gel for
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30 minutes, and the white bands of gelatin-cleared areas were sought
in the dark blue background.
Protein and IF Analysis of Cells
Cell lysis, fractionation, immunoprecipitation,Western blot, and IF
of formaldehyde-fixed cells were performed as previously described
[18,21]. The CRC frozen specimens were homogenized with a pestle
and lysed similarly in a buffer containing 1% Triton X-100, 50 mM
HEPES, pH 7.5, 100 mM NaCl, 10 mM EDTA, and 10% glycerol.
Antibodies for Western blot were obtained as follows: NHERF1,
E-cadherin, fibronectin, and β-catenin from BD Biosciences and
GAPDH (0411) and Erk2 (C-14) were from Santa Cruz Biotech-
nology (Santa Cruz, CA). For IF, the primary antibodies and cor-
responding dilutions were NHERF1 (Affinity BioReagents/Thermo)
at 1:500, E-cadherin (BDBiosciences) at 1:250, and β-catenin (Sigma-
Aldrich, St Louis, MO) at 1:500. The secondary antibodies were Alexa
Fluor 568 goat antirabbit IgG and Alexa Fluor 488 goat antimouse
IgG (Molecular Probes/Invitrogen) at 1:500, with ToPro-3 iodide
at 1:2000.
Statistics
All numerical data were examined for normality of distribution.
Parametric or nonparametric methods of one- or two-way analysis of
variance and t-test were used, as appropriate, to analyze the differences
between groups or groups by day. A 3 × 3 contingency table of cate-
gorical data from CRC case study was analyzed by Fisher exact test.
Statistical significance was considered for P < .05. Unless otherwise
indicated, values are presented as means ± SEM.
Results
NHERF1 Intracellular Localization and Levels Are
Progressively Changed in CRC Samples
To investigate the role of NHERF1 in human CRC, we analyzed a
total of 18 CRC specimens for whichmatched sets of normal, adenoma,
and carcinoma tissues were available from the surgically removed tu-
mors. Of these, 11 paraffin-embedded resection specimens contained
normal, adenoma, and carcinoma tissue on the same slide (Figure 1, A
and C ). The regions were delineated by H&E histopathologic analy-
sis, and the expression levels and subcellular localization of NHERF1
were determined by confocal IF microscopy (Figure 1, A-D). NHERF1
was expressed at the apical PM in normal colonic epithelium, and its
expression was lost in adenoma (Figure 1E ). In carcinoma, two ex-
pression patternswere observed: either absent/low expression (Figure 1,
B and E ) or ectopic overexpression in the cytoplasm (Figure 1, D and
F ). Overall, 10 of 11 adenomas and 6 of 11 carcinomas showed absent/
low NHERF1 staining, and 5 of 11 carcinomas had tumor areas with
high NHERF1 cytoplasmic staining (Figure 1G ).
To confirm these results, seven CRC cases with matched normal,
adenoma. and carcinoma frozen samples were processed for Western
blot analysis withNHERF1 antibody (Figure 1H ). As internal control,
β-catenin showedN-terminal in-frame truncation in adenoma and car-
cinoma but not in normal tissue in two cases (Figure 1H , arrowheads).
In five cases, NHERF1 showed significant depletion in both adenoma
and carcinoma samples compared with the corresponding normal tis-
sue (Figure 1H , cases 12-16 ). In the remaining two cases, NHERF1
was present in both adenoma and carcinoma samples but as a lower–
molecular weight form in comparison to the normal tissue (Figure 1H ,
cases 17-18, star). The low–molecular weight NHERF1 form most
likely represents the less phosphorylated protein that has been asso-
ciated with NHERF1 ectopic cytoplasmic expression in the intestine
of ezrin knockout mice [22].
NHERF1 Depletion Induces EMT and β-Catenin Nuclear
Translocation in Polarized Intestinal Cells
To study the effect of NHERF1 in human intestinal cells, we ana-
lyzed the subcellular distribution of NHERF1 in seven CRC cell lines
(not shown) and found that only Caco-2 cells exhibit NHERF1 apical
PM localization, similarly to normal colon epithelial cells (Figure 2A).
Caco-2 cells have been used as a model of normal intestinal cells be-
cause they form polarized cell monolayers with well-developed apical
microvilli in confluent culture [23]. We further used these cells to
model the alterations of NHERF1 observed in human CRC speci-
mens. In adenoma and carcinoma, we observed NHERF1 depletion
from the apical PM. We similarly depleted NHERF1 in Caco-2 cells
by two different shRNAs (Figure 2B) and observed scattering of the
cells with elongated or flattened shape and process extension, consis-
tent with a change towardmesenchymal morphology (Figure 2C ). The
phenotypic changes in cell shape were accompanied by a loss of the
epithelial marker E-cadherin and an increase in the mesenchymal
marker fibronectin (Figure 2B), indicating that NHERF1 loss from
the PM induces EMT in epithelial polarized cells.
Although Caco-2 cells resemble normal intestinal cells, they are
derived from CRC and have truncated Apc [24] that should inter-
fere with the degradation of β-catenin and promote its accumulation
in the nucleus. Nevertheless, β-catenin colocalized predominantly with
E-cadherin at the lateral PM in Caco-2 cells and was not observed in
the nucleus (Figure 2D, upper panels). This finding, by itself, suggests
that other events are necessary to cooperate with Apc mutations to
promote β-catenin nuclear localization. In NHERF1-depleted cells,
a dramatic increase in β-catenin nuclear localization accompanied by
a decrease from the lateral PM was apparent (Figure 2D). A parallel
E-cadherin reduction from cell-cell junctions was also observed
(Figure 2D).
Consistent with the mesenchymal-like morphologic changes,
NHERF1-depleted cells migrated significantly faster than control cells
in a monolayer scratch assay (Figure 3A). We also tested the ability of
these cells to invade through aMatrigel substrate. Control Caco-2 cells
have limited ability to invade through Matrigel. A significant increase
of invasiveness was apparent after NHERF1 depletion (Figure 3B).
The ability to invade the Matrigel requires, in addition to enhanced
cell motility, an increased activity of secreted MMPs. Using gelatin
zymography, we found a general increased activity of MMPs in super-
natant from NHERF1-depleted cells, with digestion bands suggestive
for MMP2 and MMP9 activity (Figure 3C ). The low-molecular band
could correspond to MMP7 activity, a Wnt/β-catenin transcriptional
target, or to activation products of MMP2 (Figure 3C ). Altogether,
these results suggested that loss of membrane NHERF1 in polarized
cells determines EMTand increased cell motility, most likely as a con-
sequence of β-catenin nuclear translocation.
Re-expression of Cytoplasmic NHERF1 Increases
Cell Proliferation
To confirm that the observed EMTis specifically caused byNHERF1
depletion, we reconstituted the NHERF1-depleted Caco-2 cells with
wild-type wt-NHERF1 (Figure 4, A and B). Surprisingly, ectopically
expressed untagged wt-NHERF1 did not distribute to the apical PM but
to the cytoplasm and, in some instances, to the nuclei of reconstituted
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Figure 1. Progressive changes of NHERF1 levels and intracellular localization in CRC. (A-G) Analysis of 11 resection specimens containing
normal (blue outlining), adenoma (green outlining) and carcinoma (red outlining) tissues in the same sample. CRC case 8 (A-B) and 10 (C-D)
are exemplified by H&E (A, C) and confocal IF with NHERF1 antibody and ToPro-3 (B, D). Boxes indicate the selected analyzed regions of
normal colonicmucosa and adjacent adenoma and carcinoma. Note apical PM staining of normalmucosa—arrowhead in themiddle panel
in panel B—but not of adenoma or carcinoma. Note also NHERF1 cytoplasmic overexpression in carcinoma in panel D. (E and F) Area
comparisons of membrane (E) and cytoplasmic (F) NHERF1 intensity by densitometry. N indicates normal; A, adenoma; C, carcinoma.
Data aremeans±SEMof the triplicatemeasurements for cases 8 and 10. *P< .05, **P< .001 versusN. (G) Area comparisons of NHERF1
intracellular localization by IF either at the apical PM or in the cytoplasm show significant differences (‡P < .001) between N (normal),
A (adenoma), and C (carcinoma samples). n = 11 (100%), df = degrees of freedom. (H) Western blot of whole tissue lysates from seven
additional frozen specimens showing NHERF1 expression in matched sets of normal (N), adenoma (A), and carcinoma (C) samples.
Proteins were loaded at 20 μg per lane. Lines mark the phosphorylation species of NHERF1 and star marks the less phosphorylated form,
most likely ectopically localized to the cytoplasm. Red arrowheads mark N-terminally truncated β-catenin oncogenic proteins.
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cells (Figure 4A). In addition, wt-NHERF1 neither rescued the epithe-
lial morphology of the cells (not shown) nor reestablished the expres-
sion levels and lateral membrane localization of E-cadherin (Figure 4,
A and B), clearly indicating that cytoplasmic NHERF1 does not estab-
lish epithelial morphology.
Whereas NHERF1 knockdown did not alter cell proliferation,
re-expression of wt-NHERF1 that adopted cytoplasmic localization
increased the proliferation of reconstituted cells compared with vector
control cells (Figure 4C ). A possible explanation for the increased pro-
liferation in cells with NHERF1 expressed in the cytoplasm or nucleus
could rely on the direct interaction between NHERF1 and β-catenin
with further activation of the Wnt/β-catenin pathway [11]. We in-
vestigated this possibility by immunoprecipitation of β-catenin from
cytoplasmic fractions of HT29CRC cells that express endogenous cyto-
plasmic NHERF1 (Figure 4D). RKO CRC cells that lack β-catenin
were used as a negative control. Endogenous NHERF1 could be co-
immunoprecipitated with β-catenin (Figure 4E ), indicating complex
formation between these proteins in the cytoplasm of CRC cells. Thus,
it seems that cytoplasmic NHERF1, as detected in the inner mass of
carcinomas, maintains the mesenchymal phenotype and confers addi-
tional growth advantage to cells, possibly by associating with β-catenin
outside the PM compartment.
Apical PM-Targeted NHERF1 Re-establishes the
Epithelial Morphology
The observation that wt-NHERF1 localized to the cytoplasm of
reconstituted cells but not to the apical PM prompted us to express
a membrane-targeted Myr-NHERF1 in NHERF1-depleted cells
(Figure 5, A and B). The Myr-NHERF1–reconstituted cells re-
expressed high levels of E-cadherin, specifically at the cell-cell junctions
Figure 2. NHERF1 depletion induces EMT-like changes and nuclear translocation of β-catenin in polarized Caco-2 cells. (A) Confocal IF
analysis of a Caco-2 monolayer with NHERF1 (red) and E-cadherin (green) antibodies. XZ image (top) shows NHERF1 in themicrovilli at the
apical PM, and the XY middle-plane section (bottom) shows E-cadherin at the lateral cell-cell junctions. The arrow indicates the plane of
XZ section. (B) Western blot of whole cell lysates showing NHERF1 depletion by two shRNAs (sh1 and sh4) and opposite variations of
epithelial (E-cadherin) andmesenchymal (fibronectin)markers in NHERF1-depleted cells. Proteinswere loaded at 30 μg per lane. (C) Crystal
violet staining showing EMT-like morphologic changes in NHERF1-depleted cells compared with control (vector) cells. (D) Confocal IF
with indicated antibodies shows nuclear accumulation and lateral PM effacement of β-catenin in NHERF1-depleted cells compared with
vector control cells. The densitometric analysis of β-catenin intensity for control and NHERF1-depleted cells is shown. n = 25. *P < .05,
***P < .001 versus vector.
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(Figure 6, A and B), and redistributed β-catenin from the nucleus to
the lateral PM (Figure W1A), similarly to parental Caco-2 cells. The
epithelial morphology was also restored in Myr-NHERF1–reconstituted
cells (Figure W1B), and the motility was correspondingly de-
creased to the values of the parental Caco-2 cells (Figure 5C ). This
indicated that membrane-targeted NHERF1 fully reverts both
the molecular and the cellular mesenchymal changes induced by
NHERF1 knockdown.
Surprisingly, reconstituted Myr-NHERF1 was found exclusively at
the apical PM (Figure 5, A andD, left panels), although myristoylation
is a general membrane-targeting signal. We have previously shown that
the ERM-binding region of NHERF1 is required for NHERF1 locali-
zation at themicrovilli in polarized kidney epithelial cells [25]. To exam-
ine if this region is driving the expression ofMyr-NHERF1 to the apical
PM, we reconstituted the cells with a Myr-PDZ1-2 construct contain-
ing the N-terminal PDZ domains but lacking the ERM-binding region
of NHERF1 (Figure 5D, cartoon). This form localized at the lateral
cell-cell junctions (Figure 5D, right panels), suggesting that the ERM-
binding region is the signal that targets NHERF1 to the apical PM.
Interestingly, the morphology of reconstituted Myr-PDZ1-2 cells was
intermediate between the elongatedmesenchymal appearance of control
cells and the polygonal-epithelial shape of Myr-NHERF1 cells, indicat-
ing that Myr-PDZ1-2 restored only partially the epithelial phenotype
of reconstituted cells (Figure 5E ). These findings underscore the
Figure 3. NHERF1 depletion enhances motility and promotes invasion of Caco-2 cells. (A) Scratch assay showing faster migration of
NHERF1-depleted (sh1 and sh2) cells relative to control cells. The graph shows the distance of cell migration from both ends in 48 hours.
*P < .05 versus vector (v). (B) Matrigel invasion assay at 48 hours of NHERF1-depleted (RF1-sh1) cells. *P < .05 versus vector (Vect.).
(C) Gelatin zymography showing higher activity of the secreted MMPs in supernatant from NHERF1-depleted (sh1) cells relative to vector
control cells. The supernatant was collected from samples containing an equal number of cells. Positive and negative controls are DMEM
with and without FBS, respectively. The putative molecular weights of MMP9, MMP2, and MMP7 are indicated.
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importance of NHERF1 apical PM localization in maintaining epithe-
lial morphology.
Discussion
Studies of human CRC have suggested that the accumulation of spe-
cific alterations in cell growth–regulating genes triggers the stage-wise
progression to malignancy [26]. However, the complexity of the mu-
tational signatures that accompany CRC poses the problem of which
ones are relevant for progression. In this respect, a recent study land-
scaping the genetic changes in CRC demonstrated that individual
CRC tumors accumulate approximately 90 mutant genes, most of
which are not known to contribute to tumorigenesis [27]. We describe
here NHERF1 as a new marker of CRC progression that undergoes
progressive alterations of expression and subcellular localization during
the CRC adenoma-carcinoma sequence. The normal apical PM ex-
pression of NHERF1 was lost in adenomas and replaced by cytoplas-
mic overexpresssion in approximately half of carcinomas, and these
changes modeled in polarized epithelial cell resulted in a transformed
cell phenotype (Figure 6).
We used intestinal Caco-2 cells to examine the function of
NHERF1 in CRC. Caco-2 are unusual for CRC-derived cells in that,
despite the presence of Apc and other genetic mutations [24], they
differentiate to quasi-normal polarized monolayers on reaching con-
fluency in culture [23]. Importantly, endogenous NHERF1 is ex-
pressed in the microvilli at the apical membrane similar to normal
intestinal cells, thus providing an in vitro cell system for the study
of the stage-wise progression of CRC. Loss of NHERF1, as observed
in adenoma, induced prominent epithelial morphology alterations
manifested as typical EMT-like changes. Previous studies using
NHERF1 knockdown in undifferentiated mouse embryonal carcinoma
or syncytiotrophoblast cell lines have shown a requirement for
NHERF1 only in microvilli morphogenesis [28,29]. It seems that
NHERF1 depletion triggers much more profound morphologic
changes in intestinal epithelial cells, thereby implicating NHERF1
more broadly in epithelial morphogenesis.
Surprisingly, the morphologic changes induced by NHERF1 de-
pletion in polarized epithelial cells were not reversed by expression
of wild-type NHERF1. In this instance, the expression of wild-type
NHERF1 after previous depletion of endogenous NHERF1 resulted
Figure 4. Cytoplasmic NHERF1 increases cell proliferation and associates with β-catenin. (A) Confocal IF of NHERF1-depleted cells recon-
stituted with control vector or wild-type NHERF1 (wt-NHERF1). The schematic structure of NHERF1 is shown on top of the panels.
(B) Western blot of whole cell lysates showing expression of wt-NHERF1 in NHERF1-depleted cells. Proteins were loaded at 30 μg per
lane. (C) Growth curve of wt-NHERF1–reconstituted cells, with corresponding vector controls. *P < .05 versus control (sh1 + Vwt).
(D) Subcellular fractionation of HT29 and RKO β-catenin–negative control cells. Note cofractionation of NHERF1 and β-catenin in the
cytoplasm (cyt.) and membrane (memb.) fractions of HT29 cells. E-cadherin and Erk2 were used as membrane and cytoplasmic markers,
respectively. Proteins were loaded at 20 μg per lane. (E) Coimmunoprecipitation of cytoplasmic β-catenin with NHERF1 in HT29 cells.
RKO cells were used as negative control of β-catenin expression.
Neoplasia Vol. 12, No. 12, 2010 NHERF1 Loss Induces EMT in Intestinal Epithelial Cells Hayashi et al. 1019
Figure 5.Membrane-targeting and the ERM-binding region of NHERF1 are required for epithelial reconversion of NHERF1-depleted Caco-2
cells. (A) Confocal IF analysis of NHERF1-depleted cells reconstituted with control vector or membrane-targeted NHERF1 (Myr-NHERF1).
The added N-terminal myristoylation signal is shown in green in the NHERF1 structure cartoon. Note expression of Myr-NHERF1 at the
apical PMand of E-cadherin (green) at the lateral PM. (B)Western blot ofwhole cell lysates showing restoration of E-cadherin expression by
Myr-NHERF1 expression in NHERF1-depleted cells. Proteins were loaded at 30 μg per lane. (C) Scratch assay showing slower migration
of Myr-NHERF1–reconstituted cells compared with vector control cells. The graph shows the distance of cell migration from both ends in
48 hours. *P < .05 versus +vector. (D) Confocal IF of Myr-NHERF1 and Myr-PDZ1-2–reconstituted cells showing apical and lateral PM
localization ofMyr-NHERF1 andMyr-PDZ1-2, respectively. (E) Phase-contrast images showing partial restoration of epithelial cell morphol-
ogy by Myr-PDZ1-2 compared with full restoration by Myr-NHERF1.
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in cytoplasmic and nuclear localization of the protein and a more
aggressive phenotype than the loss of NHERF1 alone. NHERF1 has
been reported to interact with β-catenin and to increase β-catenin
transcriptional activation in reporter assays [11]. In NHERF1-depleted
cells, we could already observe a shift of β-catenin to the nucleus that
most likely contributed to EMT and the increased invasiveness of cells.
However, an extra layer of Wnt/β-catenin activation may be added
after expression of aberrantly localized NHERF1, perhaps by direct in-
teractions with oncogenic β-catenin, and this could explain the increased
proliferation and lack of EMTrescue (Figure 6). In addition, disruption
of the PM localization of NHERF1 could destabilize PM complexes
with other NHERF1 ligands and lead to structural abnormalities and
increased cell invasiveness and proliferation [30]. For example, NHERF1
interacts with the ERM proteins [12], and we have shown that the
presence of NHERF1 at the apical PM is required for the proper brush
border organization and the localization of the ERMproteins in the same
compartment in intestinal epithelial cells in vivo [16]. Another member
of the ERM family, the neurofibromatosis type 2 gene product merlin,
interacts with NHERF1 in actin-rich membrane structures, such as
ruffles, microvilli, and filopodia [31], and merlin displacement from
PM has been linked to inactivation of its tumor suppressor function
[21,32]. Of note is that NHERF1 also interacts with platelet-derived
growth factor receptor and epidermal growth factor receptor [33,34],
and its removal from the PM enhances the platelet-derived growth factor
receptor–dependent signaling and cell motility [18].
Interestingly, the expression of membrane-targeted Myr-NHERF1
did rescue the EMT induced after depletion of endogenous NHERF1.
Moreover, Myr-NHERF1 localized specifically to the apical PM de-
pendent on the presence of the ERM-binding region in NHERF1.
We and others have found that in polarized opossum kidney cells ex-
ogenous NHERF1 localizes at the apical microvilli, and disruption of
the ERM-binding region either by truncation or mutation redirects it
to the cytoplasm [25,35]. Along with our findings in this study, these
observations suggest that apically localized NHERF1 is required to
maintain epithelial morphology but that it is the interaction with
ERM proteins that properly localizes NHERF1 at the apical PM.
In conclusion, this study shows that NHERF1 alterations correlate
with the progression and enhanced invasiveness of human CRC and
implicates NHERF1 as an important regulator of epithelial morphol-
ogy. Further studies are necessary to elucidate how the NHERF1 loss
from the PM and the cytoplasmic re-expression in CRC occur because
these seem to be sequential events correlated with the CRC patholog-
ical progression. Whereas we are the first to observe alterations of
NHERF1 subcellular expression in CRC and also to model the disor-
ganization of the epithelial phenotype by which these alterations lead
to progressive transformation, several similar observations have been
reported in breast cancer [36–38] and hepatocellular carcinoma
[11]. Thus, it seems that the NHERF1 loss or cytoplasmic overexpres-
sion is a more general oncogenic event in carcinomas. In this light,
efforts to restore NHERF1 to its correct PM location deserve thorough
consideration as alternative strategies for cancer treatment.
Acknowledgments
The authors thank Alan Hall for insightful discussions, Henry Adams
for help with immunofluorescence analysis, and Kerry Siegler and Toni
Castaneda for processing the resection specimens.
References
[1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008).
Cancer statistics, 2008. CA Cancer J Clin 58, 71–96.
[2] Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression.
Nat Rev Cancer 2, 442–454.
[3] Klymkowsky MW and Savagner P (2009). Epithelial-mesenchymal transition: a
cancer researcher’s conceptual friend and foe. Am J Pathol 174, 1588–1593.
[4] Schmalhofer O, Brabletz S, and Brabletz T (2009). E-cadherin, β-catenin, and
ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28, 151–166.
[5] Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, and
Ben-Ze’ev A (2003). Autoregulation of E-cadherin expression by cadherin-
cadherin interactions: the roles of β-catenin signaling, Slug, and MAPK. J Cell
Biol 163, 847–857.
[6] Yook JI, Li XY, Ota I, Fearon ER, and Weiss SJ (2005). Wnt-dependent regu-
lation of the E-cadherin repressor snail. J Biol Chem 280, 11740–11748.
[7] Roy HK, Smyrk TC, Koetsier J, Victor TA, and Wali RK (2005). The transcrip-
tional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci 50,
42–46.
[8] Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, and
Miyazaki M (2006). Slug expression is an independent prognostic parameter
for poor survival in colorectal carcinoma patients. Br J Cancer 94, 1816–1822.
[9] Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they
control. Nat Med 10, 789–799.
[10] Huang D and Du X (2008). Crosstalk between tumor cells and microenviron-
ment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol
14, 1823–1827.
Figure 6. Model of the NHERF1 alterations in the progression of CRC and of the molecular interventions in Caco-2 intestinal epithelial
cells (IECs) designed to mimic these alterations.
Neoplasia Vol. 12, No. 12, 2010 NHERF1 Loss Induces EMT in Intestinal Epithelial Cells Hayashi et al. 1021
[11] Shibata T, Chuma M, Kokubu A, Sakamoto M, and Hirohashi S (2003).
EBP50, a β-catenin–associating protein, enhances Wnt signaling and is over-
expressed in hepatocellular carcinoma. Hepatology 38, 178–186.
[12] Reczek D, Berryman M, and Bretscher A (1997). Identification of EBP50: A
PDZ-containing phosphoprotein that associates with members of the ezrin-
radixin-moesin family. J Cell Biol 139, 169–179.
[13] Weinman EJ, Steplock D, Tate K, Hall RA, Spurney RF, and Shenolikar S
(1998). Structure-function of recombinant Na/H exchanger regulatory factor
(NHE-RF). J Clin Invest 101, 2199–2206.
[14] Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-
Michalowski D, Roy JE, Cohen WA, Ramesh V, and Louis DN (2001).
NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithe-
lia, proliferative endometrium, and estrogen receptor–positive breast carcino-
mas. Am J Pathol 158, 57–62.
[15] Broere N, Chen M, Cinar A, Singh AK, Hillesheim J, Riederer B, Lunnemann
M, Rottinghaus I, Krabbenhoft A, Engelhardt R, et al. (2009). Defective jejunal
and colonic salt absorption and altered Na(+)/H (+) exchanger 3 (NHE3) ac-
tivity in NHE regulatory factor 1 (NHERF1) adaptor protein–deficient mice.
Pflugers Arch 457, 1079–1091.
[16] Morales FC, Takahashi Y, Kreimann EL, and Georgescu MM (2004). Ezrin-
radixin-moesin (ERM)–binding phosphoprotein 50 organizes ERM proteins
at the apical membrane of polarized epithelia. Proc Natl Acad Sci USA 101,
17705–17710.
[17] Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu TJ,
McCrea PD, and Georgescu MM (2007). Cortical stabilization of β-catenin
contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 26,
5290–5299.
[18] Takahashi Y, Morales FC, Kreimann EL, and Georgescu MM (2006). PTEN
tumor suppressor associates with NHERF proteins to attenuate PDGF receptor
signaling. EMBO J 25, 910–920.
[19] Molina JR, Morales FC, Hayashi Y, Aldape K, and Georgescu MM (2010). Loss
of PTEN binding adapter protein NHERF1 from plasma membrane in glioblas-
toma contributes to PTEN inactivation. Cancer Res 70, 6697–6703.
[20] Georgescu MM, Kirsch KH, Akagi T, Shishido T, and Hanafusa H (1999). The
tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.
Proc Natl Acad Sci USA 96, 10182–10187.
[21] Morales FC, Molina JR, Hayashi Y, and Georgescu MM (2010). Overexpress-
sion of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol 12,
528–539.
[22] Saotome I, Curto M, and McClatchey AI (2004). Ezrin is essential for epithelial
organization and villus morphogenesis in the developing intestine. Dev Cell 6,
855–864.
[23] Simon-Assmann P, Turck N, Sidhoum-Jenny M, Gradwohl G, and Kedinger M
(2007). In vitro models of intestinal epithelial cell differentiation. Cell Biol
Toxicol 23, 241–256.
[24] Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, and Hamelin R
(2001). Extensive characterization of genetic alterations in a series of human
colorectal cancer cell lines. Oncogene 20, 5025–5032.
[25] Morales FC, Takahashi Y, Momin S, Adams H, Chen X, and Georgescu MM
(2007). NHERF1/EBP50 head-to-tail intramolecular interaction masks associ-
ation with PDZ domain ligands. Mol Cell Biol 27, 2527–2537.
[26] Fearon ER and Vogelstein B (1990). A genetic model for colorectal tumorigen-
esis.[see comment]. Cell 61, 759–767.
[27] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, et al. (2006). The consensus coding sequences of
human breast and colorectal cancers.[see comment]. Science 314, 268–274.
[28] Chiba H, Sakai N, Murata M, Osanai M, Ninomiya T, Kojima T, and Sawada N
(2006). The nuclear receptor hepatocyte nuclear factor 4alpha acts as a morpho-
gen to induce the formation of microvilli. J Cell Biol 175, 971–980.
[29] Hanono A, Garbett D, Reczek D, Chambers DN, and Bretscher A (2006).
EPI64 regulates microvillar subdomains and structure. J Cell Biol 175, 803–813.
[30] Georgescu MM, Morales FC, Molina JR, and Hayashi Y (2008). Roles of
NHERF1/EBP50 in cancer. Curr Mol Med 8, 459–468.
[31] Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia C, Solomon F,
Gusella J, and Ramesh V (1998). NHE-RF, a regulatory cofactor for Na(+)-H+
exchange, is a common interactor for merlin and ERM (MERM) proteins. J Biol
Chem 273, 1273–1276.
[32] Curto M and McClatchey AI (2008). Nf2/Merlin: a coordinator of receptor
signalling and intercellular contact. Br J Cancer 98, 256–262.
[33] Lazar CS, Cresson CM, Lauffenburger DA, and Gill GN (2004). The Na+/H+
exchanger regulatory factor stabilizes epidermal growth factor receptors at the
cell surface. Mol Biol Cell 15, 5470–5480.
[34] Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ,
and Hall RA (2000). Platelet-derived growth factor receptor association with
Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell
Biol 20, 8352–8363.
[35] Hernando N, Deliot N, Gisler SM, Lederer E, Weinman EJ, Biber J, and Murer
H (2002). PDZ-domain interactions and apical expression of type IIa Na/P(i)
cotransporters. Proc Natl Acad Sci USA 99, 11957–11962.
[36] Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell’Aquila ME, Casavola V,
Azzariti A, Mangia A, Paradiso A, and Reshkin SJ (2007). The NHERF1 PDZ2
domain regulates PKA-RhoA-p38–mediated NHE1 activation and invasion in
breast tumor cells. Mol Biol Cell 18, 1768–1780.
[37] Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, Reshkin SJ,
Simone G, and Paradiso A (2009). Biological role of NHERF1 protein expres-
sion in breast cancer. Histopathology 55, 600–608.
[38] Song J, Bai J, Yang W, Gabrielson EW, Chan DW, and Zhang Z (2007). Ex-
pression and clinicopathological significance of oestrogen-responsive ezrin-
radixin-moesin–binding phosphoprotein 50 in breast cancer. Histopathology
51, 40–53.
1022 NHERF1 Loss Induces EMT in Intestinal Epithelial Cells Hayashi et al. Neoplasia Vol. 12, No. 12, 2010
Figure W1. Membrane-targeted Myr-NHERF1 restores the epithelial morphology in NHERF1- depleted Caco-2 cells. (A) Confocal IF anal-
ysis shows redistribution of β-catenin from nucleus to the plasma membrane in NHERF1-depleted cells reconstituted with Myr-NHERF1.
Densitometric analyses of β-catenin intensity are shown. Data are means ± SEM. n = 25. ***P < .001 versus vector. (B) Crystal violet
staining of Myr-NHERF1-reconstituted cells shows mesenchymal-to-epithelial transition–like morphological changes as compared to vector
control cells.
